PharmaShots | Incisive News in 3 Shots

Subscribe Now

 Expanded Access Program

Ocugen Reports the US FDA’s Approval of Expanded Access Program for Retinitis Pigmentosa Patients

Ocugen Reports the US FDA’s Approval of Expanded Access Program for Retinitis Pigmentosa Patients

August 6, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us